What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Two new studies suggest that the diabetes medication Ozempic may double the risk of a rare but serious condition that damages ...

A new study finds semaglutide is linked to an increased risk of vision loss associated with a rare eye condition, but cases ...

A Scandinavcian economic behemoth, Novo Nordisk is the highest-valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many ...

While the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been ... While all doses of Novo's Ozempic and Wegovy are listed as currently available in the U.S., the FDA has ...

What do many kids like most about the coming of a new year? The fireworks. Investors don't mind seeing some fireworks in their portfolios with a new year starting, either. David Jagielski (Novo ...

While Novo Nordisk's (NYSE: NVO) Ozempic has gotten most of the name recognition associated with weight-loss drugs, it's not the only drug in this category doing well. While Elon Musk recently ...

Eli Lilly's Type 2 diabetes drug Mounjaro, which shares the same active ingredient as Zepbound, outperformed Novo Nordisk's diabetes drug Ozempic (which shares Wegovy's active ingredient ...

From competing drugs outperforming Novo Nordisk’s Wegovy weight-loss solution to an investigation linking its type 2 diabetes drug Ozempic to a rare eye condition, the company is in a world of hurt.

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively quiet year ...

The decision to make such a huge investment in its manufacturing capacity comes as Novo Nordisk has been struggling to meet the demand for diabetes therapy Ozempic and obesity therapy Wegovy ...

Originally developed by Danish pharmaceutical company Novo Nordisk to manage blood sugar levels, Ozempic’s active ingredient, semaglutide, was found to cause significant weight loss. This led to ...